Cyclin-dependent kinase 2 complex (CDK2 complex)

The Cyclin-dependent kinase 2 (CDK2) complex is a vital regulator of the eukaryotic cell cycle, primarily composed of the CDK2 catalytic subunit paired with regulatory partners Cyclin E or Cyclin A [1]. This complex is essential for the G1/S phase transition and the initiation of DNA replication, where it phosphorylates key substrates such as the retinoblastoma protein (Rb) [2]. In various malignancies, including breast, ovarian, and endometrial cancers, the CDK2 complex is frequently overactivated due to the amplification of the CCNE1 gene, which encodes Cyclin E1 [3]. This dysregulation bypasses normal cell cycle checkpoints, leading to accelerated proliferation and genomic instability [4]. As a therapeutic target, CDK2 is particularly relevant in overcoming resistance to CDK4/6 inhibitors in breast cancer [5]. Modern drug discovery efforts have shifted from non-selective pan-CDK inhibitors to highly selective CDK2 inhibitors, such as PF-07104091 and BLU-222, to improve the therapeutic index and reduce hematological toxicities [6]. These agents are currently being investigated in clinical trials to treat solid tumors characterized by Cyclin E1 overexpression [7].

Other names

CDK2/Cyclin E complexCDK2/Cyclin A complexCell division protein kinase 2 complexp33(CDK2) complex

ATP-competitive inhibition of the CDK2 kinase domain, preventing the phosphorylation of downstream substrates like Rb and inhibiting E2F-mediated transcription.